Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Never miss an options trading signal again: unusual options activity screeners and strategies. FREE 30 Day Trial

Stocks | Futures | Watchlist | More
or

Charles River Laboratories Intl (CRL)

Charles River Laboratories Intl (CRL)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 11,192,401
  • Shares Outstanding, K 50,863
  • Annual Sales, $ 3,540 M
  • Annual Income, $ 390,980 K
  • 60-Month Beta 1.29
  • Price/Sales 0.33
  • Price/Cash Flow 14.47
  • Price/Book 4.37
Trade CRL with:

Options Overview Details

View History
  • Implied Volatility 34.67% ( -1.00%)
  • Historical Volatility 50.29%
  • IV Percentile 31%
  • IV Rank 24.76%
  • IV High 64.59% on 04/28/22
  • IV Low 24.83% on 09/23/21
  • Put/Call Vol Ratio 1.67
  • Today's Volume 104
  • Volume Avg (30-Day) 228
  • Put/Call OI Ratio 0.51
  • Today's Open Interest 5,065
  • Open Int (30-Day) 4,382

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 11 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/22
See More
  • Average Estimate 2.64
  • Number of Estimates 7
  • High Estimate 2.93
  • Low Estimate 2.45
  • Prior Year 2.70
  • Growth Rate Est. (year over year) -2.22%

Price Performance

See More
Period Period Low Period High Performance
1-Month
214.15 +2.80%
on 08/09/22
250.82 -12.23%
on 08/01/22
+7.55 (+3.55%)
since 07/18/22
3-Month
203.37 +8.25%
on 06/14/22
250.82 -12.23%
on 08/01/22
-4.87 (-2.16%)
since 05/18/22
52-Week
203.37 +8.25%
on 06/14/22
460.21 -52.16%
on 09/24/21
-195.93 (-47.09%)
since 08/18/21

Most Recent Stories

More News
Charles River (CRL) Business Hurt by Macro and FX Headwinds

In Q2, the impact of foreign currency translation reduces Charles River's (CRL) reported revenue growth by 3.4%.

MCK : 368.56 (+0.32%)
CRL : 220.15 (+0.05%)
PDCO : 29.62 (+0.24%)
AMN : 105.14 (-1.50%)
Charles River Laboratories is First CDMO in North America to Receive EMA Approval to Commercially Produce an Allogeneic Cell Therapy Drug Product

Charles River Laboratories, International Inc. (NYSE: CRL) announced it has received regulatory approval, in the form of Good Manufacturing Practice (GMP) certification, to commercially produce allogeneic...

CRL : 220.15 (+0.05%)
Charles River (CRL) Q2 Earnings Top Estimates, 2022 View Cut

Revenue decline in the CDMO business drag Charles River's (CRL) Manufacturing Solutions revenues down.

MRK : 91.40 (+0.40%)
DGX : 135.96 (-1.36%)
CRL : 220.15 (+0.05%)
MEDP : 174.44 (-1.35%)
Charles River Laboratories (CRL) Beats Q2 Earnings Estimates

Charles River (CRL) delivered earnings and revenue surprises of 1.09% and 2.54%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

CRL : 220.15 (+0.05%)
AGL : 20.71 (-1.85%)
Charles River Laboratories Announces Second-Quarter 2022 Results

Charles River Laboratories International, Inc. (NYSE: CRL) today reported its results for the second quarter of 2022. For the quarter, revenue was $973.1 million, an increase of 6.4% from $914.6 million...

CRL : 220.15 (+0.05%)
MedTech Stocks to Watch for Earnings on Aug 3

MedTech players are likely to have benefited from the consistent opening of economies and sales contributions from high testing demand. Let's see how CRL, CVS, BRKR and NUVA fare this time.

CVS : 103.64 (-1.22%)
CRL : 220.15 (+0.05%)
NUVA : 50.83 (+0.77%)
BRKR : 61.46 (+0.05%)
Charles River Laboratories (CRL) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

Charles River (CRL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

CRL : 220.15 (+0.05%)
Charles River (CRL) to Report Q2 Earnings: What's in Store?

The broad-based demand and meaningful price increases in the RMS business, particularly in North America and China, are expected to have contributed to Charles River's (CRL) Q2 top line.

ALC : 68.93 (+0.38%)
CRL : 220.15 (+0.05%)
GKOS : 51.12 (+0.06%)
BWAY : 5.00 (-3.29%)
Stocks Gains Evaporate as Apple Plans to Slow Hiring and Spending

What you need to know… The S&P 500 Index ($SPX ) (SPY ) on Monday closed down -0.84%, the Dow Jones Industrials Index ($DOWI ) (DIA ) closed down -0.69%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) closed...

$SPX : 4,283.74 (+0.23%)
SPY : 427.89 (+0.29%)
$DOWI : 33,999.04 (+0.06%)
DIA : 340.58 (+0.11%)
$IUXX : 13,505.99 (+0.26%)
QQQ : 329.28 (+0.24%)
AAPL : 174.15 (-0.23%)
SGEN : 169.09 (-1.00%)
BIO : 519.57 (-0.87%)
DHR : 294.27 (-1.01%)
TMO : 595.01 (-0.17%)
CRL : 220.15 (+0.05%)
These 2 Stocks May Be Recession-Proof

While many companies worry about the global economy, Charles River and Thermo Fisher are optimistic.

CRL : 220.15 (+0.05%)
TMO : 595.01 (-0.17%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Charles River Laboratories International, Inc. is a full service, early-stage contract research organization. The company provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions globally accelerate their research...

See More

Key Turning Points

3rd Resistance Point 226.69
2nd Resistance Point 224.04
1st Resistance Point 222.10
Last Price 220.15
1st Support Level 217.50
2nd Support Level 214.85
3rd Support Level 212.90

See More

52-Week High 460.21
Fibonacci 61.8% 362.10
Fibonacci 50% 331.79
Fibonacci 38.2% 301.48
Last Price 220.15
52-Week Low 203.37

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar